Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. Academic Article uri icon


  • Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

published proceedings

  • NPJ Regen Med

altmetric score

  • 10.072

author list (cited authors)

  • Shetty, A. K., Shetty, P. A., Zanirati, G., & Jin, K.

citation count

  • 3

complete list of authors

  • Shetty, Ashok K||Shetty, Padmashri A||Zanirati, Gabriele||Jin, Kunlin

publication date

  • January 2021